Singapore’s Gender Medicine Guidelines Are Close To Being The Global Gold Standard

MOH Circular 44/2026 places Singapore among six health systems that have arrived at the same conclusion. The unfinished work is social transitioning.

On 5 May 2026, Professor Kenneth Mak, Director-General of Health, signed MOH Circular No. 44/2026 and sent it to every registered medical practitioner in Singapore. The subject was treatment guidelines for children and adolescents with gender dysphoria.

Two annexes followed.

These were drafted by multidisciplinary clinical workgroups and endorsed by the Academy of Medicine Singapore. Together, they set the professional standard for clinicians treating gender-dysphoric Singaporeans under twenty-one.

Within roughly a week, the circular and both annexes were pulled from the Healthcare Services Act licensing portal. A part remains accessible through the Wayback Machine.

Bernard Lane, who covers paediatric gender medicine for Gender Clinic News, flagged the disappearance on 12 May. Activists on Reddit speculated about a reversal of policy or a cover-up. Neither reading survives scrutiny.

The day after the circular was issued, Minister for Health Ong Ye Kung confirmed its terms in Parliament in answer to a question from Dr Wan Rizal of Jalan Besar GRC. The circular itself reached every public hospital and registered doctor through the MOH Alert system, bypassing any public-facing webpage.

The standard remains in force.

What Singapore Did

The substance of the policy is more striking than its muted rollout.

The guidelines require gender dysphoria to be managed by a multidisciplinary team, to be treated sequentially with psychological care first, and to never receive hormonal and surgical interventions under eighteen.

For Singaporeans aged eighteen to twenty, hormonal therapy is permitted only in exceptional circumstances where there is clear evidence of benefit or harm reduction, with consensus from a mandatory Treatment Review Panel that must include one non-treating medical specialist, and informed consent from both the patient and both parents.

Both-parent consent applies even for adolescents who are otherwise legally adults.

Pubertal suppression is not recommended at all, in line with NHS England’s position of March 2024. Mandatory fertility counselling with both parents must precede any hormonal initiation.

The age of maturity for treatment decisions is twenty-one rather than eighteen.

Capacity assessment requires confirmation that a patient is not, in the guidelines’ own phrasing, acting under undue influence of other persons or information, whether interacting in person or online.

The Treatment Review Panel includes a non-treating specialist precisely so that decisions are objective rather than driven by the affirmation of clinicians who have already taken a political position.

These are wonderfully careful guidelines by international standards. Singapore has done its homework.

Singapore’s Rejection of the Affirmation Model

The single strongest affirmation came from lawmakers. In his parliamentary answer, Minister Ong confirmed that the Ministry of Health, the Ministry of Social and Family Development, and the Ministry of Education had jointly refreshed the national Counselling Guidelines.

Therapists working with youths are now directed to provide non-judgmental and objective care, and to “avoid influencing youths or their families towards a pre-determined outcome”.

That is a direct repudiation of the affirmation model. Affirmation has a pre-determined outcome by design; the clinician’s task is to validate the asserted identity and facilitate transition. A counselling practice committed to no pre-determined outcome is incompatible with affirmation.

Rapid-Onset Gender Dysphoria – a Contagion In Singapore

The need for these standards is not hypothetical. Singapore has its own contagion data.

The most rigorous local study, a 2024 retrospective analysis by Goh and colleagues at the Institute of Mental Health’s Child Guidance Clinic, tracked every patient diagnosed with gender dysphoria at the clinic from 2017 to 2021.

New presentations rose from 2.17 per 100,000 population in 2017 to 5.85 per 100,000 in 2021, nearly tripling in four years. The cohort was 107 patients aged six to nineteen, with a mean age at diagnosis of around sixteen.

The rate increase is a curve that a stable biological trait does not produce.

High psychiatric comorbidity was the rule rather than the exception: 67 per cent carried at least one additional diagnosis, most commonly a mood disorder, with autism spectrum disorder, anxiety and ADHD also prevalent.

Children’s Guidelines

The Children’s Guidelines do not flinch from the inference.

They cite De Vries (2011) and the American College of Pediatricians on the well-established finding that 80 to 95 per cent of prepubertal children with gender dysphoria do not persist in it.

They warn that high subscription for puberty suppression can be self-fulfilling, encouraging a young child to socially impersonate the opposite sex in ways that produce the outcome the intervention claims to be measuring.

They direct clinicians not to prematurely or excessively endorse and affirm a child’s gender identity. Among the legitimate aims of family-focused therapy, they list “supporting parents to allow the child freedom to return to a gender identity that aligns with sex assigned at birth”.

That formulation would be classified as conversion therapy and prohibited by law in several “progressive” Western jurisdictions. In Singapore, the Ministry of Health treats it as standard clinical practice.

Bravo!

Shadow Medicine

When the circular was published, discussions on the local Reddit forum r/sglgbt inadvertently provided the perfect case for justifying the new guidelines. The thread documented a functioning parallel system of unsupervised medicalisation.

Users shared accounts of a nineteen-year-old self-medicating on endocrine drugs since age seventeen via unofficial sources, a licensed local clinic monitoring bloodwork for patients on self-procured unprescribed hormones, and suggestions of cross-border procurement from Thailand.

Commenters framed parents who opposed their children’s self-medication as transphobic obstacles to life-saving treatment. Senior community members advised continuing DIY hormone regimens without medical supervision.

Read structurally rather than personally, the thread confirms what the Ministry already knew: a shadow medical system was operating outside any clinical governance framework.

The Adolescent Guidelines address this directly, noting that patients on self-procured hormones must be assessed for prescription suitability and counselled on the risks of contamination and inappropriate dosing.

That a national clinical guideline has to specify this is itself instructive.

The Adolescent Guidelines and Long-Term Outcomes

The Adolescent Guidelines apply the same realism to the question of whether medical transition resolves the underlying distress it is meant to treat.

The guidelines cite the foundational 2011 Swedish study by Dhejne and colleagues, published in PLoS ONE by the Karolinska Institutet and drawn from the full Swedish national registry.

The study followed 324 post-operative sex-reassigned persons over three decades and found that suicide mortality ran 19.1 times higher than the matched general population, all-cause mortality 2.8 times higher, and psychiatric inpatient care 2.8 times higher. Survival curves began diverging from controls approximately ten years after surgery.

MOH includes this study to make a precise clinical point. Medical and surgical transition does not reliably resolve the psychological distress that drives the presentation.

It is a relevant point because the primary activist justification for urgent paediatric intervention is the prevention of suicide. The data from the most comprehensive long-term follow-up study in the literature, cited in the Ministry’s own guidelines, do not support that justification.

The Convergence with A Growing Global Consensus

Singapore is not acting alone. Five Western health systems independently reached the same conclusion within roughly five years.

• The Cass Review, the most thorough independent investigation of paediatric gender medicine ever commissioned, concluded in April 2024 that the evidence base for medical transition in minors was remarkably weak. Hilary Cass and her team commissioned systematic reviews from the University of York and found that almost every study supporting hormonal intervention suffered from serious methodological problems. NHS England banned routine prescription of puberty blockers for gender dysphoria in the same month.

• Sweden’s National Board of Health and Welfare arrived at a similar position in 2022, restricting medical interventions to research settings on the grounds that risks outweighed benefits.

• Finland’s national health authority, COHERE, had reached the same conclusion in 2020, recommending psychotherapy rather than medical intervention as the first-line treatment.

• Norway’s Healthcare Investigation Board followed in 2023, classifying paediatric medical transition as experimental.

• In November 2025, the United States Department of Health and Human Services published its peer-reviewed final report on gender dysphoria in minors, rating the evidence quality for hormonal and surgical interventions as very low and recommending psychotherapeutic approaches, including exploratory therapy, as the primary response.

Singapore’s circular places it in that company, and on several measures more cautious than most. The UK and Nordic systems set the threshold for adult treatment at eighteen. Singapore sets it at twenty-one, with the eighteen-to-twenty band governed by Treatment Review Panel approval and dual parental consent. None of the other systems has the equivalent of the joint counselling-guidelines refresh.

Gender Activists Crash Out

This matters because of how the activist position has responded to the evidence.

Between 2020 and 2025, six independent systematic reviews in liberal Western democracies converged on the conclusion that the case for paediatric medical transition was poor. None was conducted by a religious body, a conservative think-tank, or an organisation with a stated ideological commitment to either side. Each was commissioned by a national health authority working from existing peer-reviewed literature.

In response, foreign gender-affirming clinicians and advocacy groups did not update their position. They attacked the reviewers instead, calling Cass (who personally aligns with social progressives) transphobic, accusing NHS England of bowing to bigotry, ignoring or denouncing the Nordic reviews, and dismissing the HHS report as politically motivated despite its peer review.

A Regardless piece, Transgender Activists Are At War With Reality, Not MOH, treats the local manifestation of the same pattern directly.

A scientific position updates when evidence updates. The diagnostic test is the one any clinician applies to a stuck hypothesis: when six independent reviews of the same body of evidence reach the same answer, the parsimonious move is to take the answer seriously rather than to attack the reviewers.

The activist refusal to do so signals that what is being defended is not a body of clinical knowledge but an ideological worldview.

Outside the affirming clinics, a parallel professional and lay infrastructure has emerged. The Society for Evidence-Based Gender Medicine and the Clinical Advisory Network on Sex and Gender hold the clinical ground. Genspect and Our Duty hold the parental ground. Sex Matters and the LGB Alliance hold the legal and policy ground.

Materials produced by several of these bodies featured in the literature Cass reviewed. They are now the mainstream of evidence-based engagement with the question.

Singapore Media Has Not Updated

Singapore’s domestic media establishment has not made the same adjustment. The Straits Times and Channel NewsAsia have routinely presented gender-identity affirmation as settled clinical consensus. Both outlets have profiled individuals sympathetically without engaging the shifting evidence base, treated advocacy organisations as authoritative sources on paediatric medicine, and given no meaningful coverage to the Cass Review, the Nordic restrictions, or the HHS report.

The precise charge is not extremism. It is that their baseline was set by Western activist framing at a particular moment, and has not moved since.

The Cass Review was published in April 2024. The NHS England ban followed in the same month. The HHS report was published in November 2025. None of these featured as significant news events in either outlet’s coverage of gender medicine.

Their past reporting on affirmation-model clinicians and WPATH guidance as authoritative now stands in direct contradiction with the Ministry of Health’s evidence-based position. That is an editorial problem their editors are best placed to address.

Singapore’s Unfinished Business

Singapore did well on medical and surgical intervention. The harder question, and the one the guidelines do not yet answer, is social transitioning.

Social transitioning is the set of steps that come before any medication: a change of name, change of pronouns, change of clothing, sometimes a change of uniform or facilities, and the cooperation of schools and parents in treating a child as the opposite sex.

Advocates have presented it as reversible and neutral. The evidence does not support that framing.

The Children’s Guidelines, on page fourteen of the Relevant MOH Annex, acknowledge the difficulty in their own words. There is, the document states, currently no conclusive evidence on whether children should undertake social transitioning.

The same paragraph then notes that “social transitioning is associated with persistence of dysphoria from childhood to adolescence”, citing Ehrensaft and colleagues (2018).

The guidelines decline to recommend either for or against it, leaving the most consequential pre-medical decision in the gender-dysphoria pathway without clinical guidance.

The Cass Review reached further. Cass classified social transition as “an active intervention” rather than a neutral step, noting absence of robust evidence of benefit and observing that early social transition can change the trajectory of a child’s psychological development. The accompanying systematic review from the University of York reached the same conclusion.

The cohort data is sharper still. Olson and colleagues, in a 2022 paper in Pediatrics, followed three hundred and seventeen children who had socially transitioned at an average age of six and a half.

Five years later, 97.5 per cent continued to identify as transgender. Sixty per cent had started puberty blockers or cross-sex hormones by ages eleven to twelve. The authors framed the results as reassuring evidence that early socially transitioned children rarely revert.

Read against the historic desistance rate of 80 to 95 per cent without social transition, the same numbers run the other way. Social transition collapses the desistance pathway and routes children into medicalisation at puberty.

The Steensma study from 2013, which the MOH guidelines themselves cite as evidence for the 85 per cent desistance figure, contains the mechanism. Among birth-assigned males classified as persisters, 43 per cent had socially transitioned before puberty. Among desisters, the figure was 3.6 per cent. Social transition was the single strongest predictor of persistence in the data.

Cass observed of the Tavistock Gender Identity Development Service that almost every child referred for medical intervention had already socially transitioned, often with school cooperation, often before any clinical assessment had taken place. The medical decision was in practice, downstream of a social decision already made.

This puts the Singapore policy in an awkward position.

A system that prohibits medical intervention until eighteen, but permits and accommodates social transition at, hypothetically, seven, is a system that produces eighteen-year-olds who have lived as the opposite sex for a decade.

The Treatment Review Panel that must, at eighteen, decide whether to authorise hormonal therapy in exceptional circumstances will face a young adult whose entire social, educational and familial life has been organised around the affirmed gender.

The threshold for denying medical intervention in such a case is almost impossible to apply. The social step does the work the medical step was prohibited from doing.

What Remains

MOH Circular 44/2026 is a serious piece of policymaking and a real contribution to a debate that other jurisdictions have either avoided or got wrong.

Singapore has set its age of majority for medical treatment at twenty-one, required both-parent consent for the eighteen-to-twenty band, banned puberty suppression, ruled out medical and surgical intervention for minors, instituted Treatment Review Panel oversight with a non-treating specialist, and aligned counselling practice with the requirement of no pre-determined outcome.

Across the relevant axes, the Singapore standard is arguably the gold standard and now more cautious than the Cass-aligned NHS standard.

The work that remains is on social transition. The Ministry’s own Children’s Guidelines name the association with persistence, yet, decline to act on it.